<p>Prestige Consumer (NYSE:PBH) will release its quarterly earnings report on Thursday, 2026-02-05. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Prestige Consumer to report an <strong>earnings per share</strong> (EPS) of $1.16.</p>
<p>The announcement from Prestige Consumer is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Performance in Previous Earnings</h3>
<p>The company's EPS beat by $0.09 in the last quarter, leading to a 2.3% drop in the share price on the following day.</p>
<p>Here's a look at Prestige Consumer's past performance and the resulting price change:</p>
<p></p><table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th align="right"><strong>Q2 2026</strong></th>
<th align="right"><strong>Q1 2026</strong></th>
<th align="right"><strong>Q4 2025</strong></th>
<th align="right"><strong>Q3 2025</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td align="right">0.98</td>
<td align="right">1.00</td>
<td align="right">1.29</td>
<td align="right">1.16</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td align="right">1.07</td>
<td align="right">0.95</td>
<td align="right">1.32</td>
<td align="right">1.22</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td align="right">-2.00</td>
<td align="right">-3.00</td>
<td align="right">0.00</td>
<td align="right">0.00</td>
</tr>
</tbody>
</table><p></p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770235267_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="eps graph" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770235267_0.png"/></p>

<h3>Prestige Consumer Share Price Analysis</h3>
<p>Shares of Prestige Consumer were trading at $64.43 as of February 03. Over the last 52-week period, shares are down 23.45%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<h3>Analyst Observations about Prestige Consumer</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Prestige Consumer.</p>
<p>A total of 2 analyst ratings have been received for Prestige Consumer, with the consensus rating being Buy. The average one-year price target stands at $77.0, suggesting a potential 19.51% upside.</p>
<h3>Comparing Ratings Among Industry Peers</h3>
<p>In this comparison, we explore the analyst ratings and average 1-year price targets of Tarsus Pharmaceuticals, Supernus Pharmaceuticals and Ligand Pharmaceuticals, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Outperform trajectory for Tarsus Pharmaceuticals, with an average 1-year price target of $100.0, suggesting a potential 55.21% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Supernus Pharmaceuticals, with an average 1-year price target of $55.0, suggesting a potential 14.64% downside.</li>
<li>Analysts currently favor an Buy trajectory for Ligand Pharmaceuticals, with an average 1-year price target of $242.14, suggesting a potential 275.82% upside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
<p>The peer analysis summary provides a snapshot of key metrics for Tarsus Pharmaceuticals, Supernus Pharmaceuticals and Ligand Pharmaceuticals, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p></p><table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prestige Consumer</td>
<td>Buy</td>
<td>-3.41%</td>
<td>$151.58M</td>
<td>2.29%</td>
</tr>
<tr>
<td>Tarsus Pharmaceuticals</td>
<td>Outperform</td>
<td>146.68%</td>
<td>$110.39M</td>
<td>-3.77%</td>
</tr>
<tr>
<td>Supernus Pharmaceuticals</td>
<td>Neutral</td>
<td>9.34%</td>
<td>$173.14M</td>
<td>-4.27%</td>
</tr>
<tr>
<td>Ligand Pharmaceuticals</td>
<td>Buy</td>
<td>122.85%</td>
<td>$111.66M</td>
<td>13.19%</td>
</tr>
</tbody>
</table><p></p>
<p>Key Takeaway:</p>
<p>Prestige Consumer ranks at the bottom for Revenue Growth and Gross Profit, while it ranks in the middle for Return on Equity.</p>
<h3>Get to Know Prestige Consumer Better</h3>
<p>Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.</p>
<h3>Breaking Down Prestige Consumer's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Prestige Consumer's financials over 3 months reveals challenges. As of 30 September, 2025, the company experienced a decline of approximately <strong>-3.41%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Prestige Consumer's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>15.4%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>2.29%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.23%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.57</strong>.</p>
<p>To track all earnings releases for Prestige Consumer visit their earnings calendar on our site.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>

<p>Prestige Consumer (NYSE:PBH) is set to release its quarterly earnings report on February 5, 2026, with analysts expecting an EPS of $1.16. The company previously beat EPS estimates by $0.09, but shares fell 2.3% afterward. Currently trading at $64.43, Prestige Consumer's stock is down 23.45% over the past year. Analysts rate the stock as a Buy, with a one-year price target of $77.0, indicating a potential upside of 19.51%. The company faces challenges with revenue growth, reporting a decline of 3.41%, but maintains a strong net margin of 15.4%.</p>

Prestige Consumer's Earnings: A Preview